Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC(+) tumors respond to PD1/PD-L1 blockade therapy

por Zhang, Jinyu, Larrocha, Pablo Saenz-lopez, Zhang, Bin, Wainwright, Derek, Dhar, Payal, Wu, Jennifer D.
Publicado 2019